Breaking Through Boundaries in Prostacyclin Therapies

Watch a video on PRINT® Technology

Still image from the PRINT Technology video
 

YUTREPIA LEVERAGES PRINT® TECHNOLOGY TO PRODUCE PARTICLES DESIGNED TO ENHANCE DEEP-LUNG DELIVERY1-3

Milled particles - Various sizes and shapes

Milled particles
Various sizes and shapes

TRADITIONAL DRY POWDER FORMULATIONS
  • Manufactured using a milling process
  • Produces clumps of dry powder particles of various sizes and shapes
  • Requires a patient's inspiratory effort to break apart the medication
YUTREPIA particles - Uniform ~1 µm size and shape

YUTREPIA particles
Uniform ~1 µm size and shape

PRINT® FORMULATION1,4-12
  • Manufactured using a proprietary technology called PRINT® (Particle Replication In Non-wetting Templates)
  • Drug particles are uniform in size and shape (~1 µm), engineered for enhanced aerosolization and deep-lung deposition of treprostinil
  • Reduced chance of drug particles sedimenting in the upper respiratory tract
  • PRINT® formulation is designed to improve tolerability and allow for higher dose achievement
The YUTREPIA formulation is specifically engineered with uniformly small particlesYUTREPIA particle size deep lung delivery diagram
 

YUTREPIA IS DELIVERED VIA A CONVENIENT AND TRUSTED LOW-EFFORT DEVICE1,4-6,14,15*

Image of YUTREPIA inhaler
LOW EFFORT
  • YUTREPIA's low-resistance device requires minimal inspiratory effort to deliver a dose of treprostinil*†
  • Device is not position-dependent, which may reduce the risk of patient error, spillage, or wasted medication4
CONVENIENT
  • Device is a robust, pocket-sized DPI
  • Both the device and drug capsules are portable and require no refrigeration13
TRUSTED
  • The Plastiape RS00 is a low-effort* device that was previously approved by the FDA and EMA4-6,14
  • Device has been used for decades across respiratory disease states15

PATIENT-PREFERRED DELIVERY DEVICE1,‡

100% of patients who transitioned from TYVASO preferred or strongly preferred YUTREPIA after 4 months of use

Defined as low inspiratory effort.5,6

The amount of drug delivered to the lungs will vary depending on patient factors such as inspiratory flow and peak inspiratory flow through the inhalation device, which may vary from patient to patient.

Patients in the transition group of INSPIRE were surveyed at month 4 on their preference for the YUTREPIA RS00 Model 8 DPI device compared with their previously used device, the TYVASO® nebulized treprostinil inhalation system. Patients were asked if they preferred the old inhalation system, had no preference, preferred the new inhaler, or strongly preferred the new inhaler.

dpi=dry-powder inhaler; EMA=European Medicines Agency; IPF=idiopathic pulmonary fibrosis.

TYVASO is a registered trademark of United Therapeutics Corporation.

References

  1. Hill NS, Feldman JP, Sahay S, et al; INSPIRE study investigators. INSPIRE: safety and tolerability of inhaled Yutrepia (treprostinil) in pulmonary arterial hypertension (PAH). Pulm Circ. 2022;12(3):e12119. doi:10.1002/pul2.12119
  2. Garcia A, Mack P, Williams S, Fromen C, et al. Microfabricated engineered particle systems for respiratory drug delivery and other pharmaceutical applications. J Drug Deliv. 2012;2012:941243. doi:10.1155/2012/941243
  3. Roscigno RF, Vaughn T, Parsley E, Hunt T, et al. Comparative bioavailability of inhaled treprostinil administered as LIQ861 and Tyvaso® in healthy subjects. Vascul Pharmacol. 2021;138:106840. doi:10.1016/j.vph.2021.106840
  4. Patel S, Prabel J, MacLennan D, Rosen G. Robustness of YUTREPIA™, a dry-powder inhaled formulation of treprostinil, in patient misuse scenarios. Poster presented at: CHEST 2022 Annual Meeting; October 16-19, 2022; Nashville, TN.
  5. Price D, Chrystyn H. Concept review of dry powder inhalers: correct interpretation of published data. Multidiscip Respir Med. 2015;10:36. doi:10.1186/s40248-015-0033-0
  6. National Health Service Sunderland. Sunderland COPD Inhaler Guide. National Health Service; 2020.
  7. Simon MA, Shapiro SM, Sahay S, et al. Clinical outcomes of YUTREPIA™ dose in 6MWD and quality of life. Poster presented at: CHEST 2022 Annual Meeting; October 16-19, 2022; Nashville, TN.
  8. Data on file. Liquidia Technologies, Inc.
  9. Chaurasiya B, Zhao YY. Dry powder for pulmonary delivery: a comprehensive review. Pharmaceutics. 2020;13(1):31. doi:10.3390/pharmaceutics13010031
  10. Roscigno RF, Farrer BT, Sprague JJ, Maynor B, inventors; Liquidia Technologies, Inc, assignee. Dry powder Treprostinil for the treatment of pulmonary hypertension. US patent application 16/099,135. May 5, 2017.
  11. Henao MP, Kraschnewski JL, Bolton MD, Ishmael F, Craig T. Effects of inhaled corticosteroids and particle size on risk of obstructive sleep apnea: a large retrospective cohort study. Int J Environ Res Public Health. 2020;17(19):7287. doi:10.3390/ijerph17197287
  12. Maynor BW, Anderson S, Vaughn T, et al. Nonclinical, in-silico, and clinical evaluation of LIQ861 inhalation powder deposition and pharmacokinetics. Respir Drug Deliv. 2020;2:371-374.
  13. YUTREPIA. Prescribing information. Liquidia Technologies, Inc; 2025.
  14. Kingman M, Patel S. Quality of life (QoL) in PAH patients receiving an inhaled dry powder Treprostinil (LIQ861) in the INSPIRE study. Poster presented at: PHA International PH Conference and Scientific Sessions; June 9-11, 2022; Atlanta, GA.
  15. World Pharmaceutical Frontiers. Keep it simple and single. Updated November 5, 2015. Accessed December 20, 2025. https://www.worldpharmaceuticals.net/contractors/drug-delivery-systems/plastiape/
  16. Hill NS, Feldman JP, Sahay S, et al; INSPIRE study investigators. INSPIRE: safety and tolerability of inhaled Yutrepia (treprostinil) in pulmonary arterial hypertension (PAH). Pulm Circ. 2022;12(3)(suppl):e12119. doi:10.1002/pul2.12119